Compare · HYPR vs SLNO
HYPR vs SLNO
Side-by-side comparison of Hyperfine Inc. (HYPR) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPR and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 19.7x HYPR ($140.0M).
- Over the past year, HYPR is up 79.9% and SLNO is down 31.8% - HYPR leads by 111.7 points.
- SLNO has been more active in the news (39 items in the past 4 weeks vs 11 for HYPR).
- SLNO has more recent analyst coverage (12 ratings vs 4 for HYPR).
- Company
- Hyperfine Inc.
- Soleno Therapeutics Inc.
- Price
- $1.41+0.36%
- $53.02+0.08%
- Market cap
- $140.0M
- $2.76B
- 1M return
- -16.86%
- +0.76%
- 1Y return
- +79.90%
- -31.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 11
- 39
- Recent ratings
- 4
- 12
Hyperfine Inc.
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest HYPR
- SEC Form 4 filed by Director Wolterman Dan
- CFO and CAO Hale Brett sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 1.00% to 599,765 units (SEC Form 4)
- Chief Operating Officer Teisseyre Thomas sold $9,978 worth of shares (6,047 units at $1.65), decreasing direct ownership by 0.88% to 678,601 units (SEC Form 4) (withholding obligation)
- Hyperfine to Join Russell 2000® and Russell 3000® Indexes
- SEC Form 4 filed by Director Fattori Ruth A
- SEC Form 4 filed by Director Wolterman Dan
- SEC Form 4 filed by Director Dahldorf John T
- SEC Form 4 filed by Director Rothberg Jonathan M
- Hyperfine Announces Presentation of Results from the PRIME Study Showing Portable MRI Substantially Reduces Time to Imaging in Emergency Departments
- SEC Form EFFECT filed by Hyperfine Inc.
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)